(Q44783744)

English

Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults

scientific article published in January 2004

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

1 reference

based on heuristic

inferred from title

author name string

Lala Mathers Dunbar

1

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Joseph Hassman

2

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Guy Tellier

3

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

publication date

1 January 2004

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Clinical Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

26

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

48-62

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990005-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990005-7

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro activities of the new ketolide antibiotics HMR 3004 and HMR 3647 against Streptococcus pneumoniae in Germany.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990005-7

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990005-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The macrolide-ketolide antibiotic binding site is formed by structures in domains II and V of 23S ribosomal RNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990005-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells by 11 different ketolide antibiotics.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990005-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Susceptibilities of Penicillin- and Erythromycin-Susceptible and -Resistant Pneumococci to HMR 3647 (RU 66647), a New Ketolide, Compared with Susceptibilities to 17 Other Agents

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990005-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative antimicrobial activity and kill-curve investigations of novel ketolide antimicrobial agents (HMR 3004 and HMR 3647) tested against Haemophilus influenzae and Moraxella catarrhalis strains

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990005-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990005-7

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990005-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990005-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647).

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990005-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Lung concentrations of telithromycin after oral dosing

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990005-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A prediction rule to identify low-risk patients with community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990005-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Rapid diagnosis of Legionella pneumophila serogroup 1 infection with the Binax enzyme immunoassay urinary antigen test

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990005-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identification of Chlamydia pneumoniae by DNA amplification of the 16S rRNA gene

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990005-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Diagnosis of Chlamydia pneumoniae infection in patients with community-acquired pneumonia by polymerase chain reaction enzyme immunoassay

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990005-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990005-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Evolving resistance patterns of Streptococcus pneumoniae: a link with long-acting macrolide consumption?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990005-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Development of antibacterial resistance: the Dutch experience

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990005-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Azithromycin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990005-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of grepafloxacin 600 mg daily for 10 days in patients with community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990005-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Clarithromycin versus amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990005-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparative safety and efficacy study of clarithromycin and erythromycin stearate in community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990005-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Azithromycin. A review of its pharmacological properties and use as 3-day therapy in respiratory tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990005-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Clarithromycin. A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990005-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0149-2918(04)90005-7

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44783744&oldid=2041111339"